\"

Conference Day Two

8:15 AM - 8:55 AM Registration and Welcome Coffee and Tea

8:50 AM - 9:00 AM Chairman's Recap of Day One

9:00 AM - 9:45 AM Coordination and Optimisation of External Data Sources in the Drug Development Process

Mats Sundgren, Principal Scientist, AstraZeneca
• Establish a data system framework to amalgamate external Electronic Health Information data
• Effectively integrate external EHI data into the drug developmental process
• Utilize a combination of data sources to effectively structure your developmental strategy

Mats Sundgren

Principal Scientist
AstraZeneca

9:45 AM - 10:30 AM How Data Analytics Can be Used to Optimise the Performance of Clinical Trials

Joanne North, Senior Director of Clinical Quality Assurance , GlaxoSmithKline R&D
• Move towards the precision trial – the role of big data analytics in streamlining the clinical development process
• Incorporate ‘Quality Data’ as a means of validity testing clinical hypothesis in early stage development
• Utilise predictive analytics to forecast key risk areas and potential mitigation strategies

Joanne North

Senior Director of Clinical Quality Assurance
GlaxoSmithKline R&D

10:30 AM - 11:00 AM Networking Coffee Break

11:00 AM - 11:40 AM IMI Real World Data Programmes – What Have we Learned and What is Next?

Nigel Hughes, Scientific Director, Janssen
• Identify the key challenges to health research in the EU
• Respond effectively to the rapid need for RWD: use cases from EHR4CR, EMIF and others
• Discuss what lies in the Pharma future: new programmes and new opportunities

Nigel Hughes

Scientific Director
Janssen

11:40 AM - 12:15 PM Identifying, Integrating & Interpreting Real World Data

• Navigate the complex and disparate landscape of real world data sources to identify the assets of most value to your business
• Incorporate company strategy into your Real World Data procurement to ensure valuable insights
• Establish an enterprise level framework for data procurement, management and governance

12:15 PM - 12:50 PM Enhance the Application and Validity of Assessment and Monitoring of Pharmaceutical Interventions – Case Study

• Discuss the current paradigm emerging through the Internet of Things (IoT)
• Examine the role of Patient Reported Outcome Measures (PROMs)
• Understand the relevance of Digitised Observed Report Measures (DORMs)

12:50 PM - 1:50 PM Networking Lunch

1:50 PM - 2:30 PM Solving the Precision Medicine Puzzle – the Role of Predictive Analytics

• Utilise predictive modelling as a means of identifying ‘high probability’ novel molecules for development
• Integrate biomarker research and treatment personalization into the clinical development process to ensure the generation of high value data
• Employ bio and digital markers to inform the decision making process and improve your risk-benefit profiling

2:30 PM - 3:10 PM How Could Big Data Change the Face of Product Reimbursement

Mike Spencer, Head of Real World Evidence, EMEA, Janssen
• Manage the transition from a unit-based pricing system to a value based pricing system
• Streamline your payer approval by maximizing the impact of Real World Evidence Metrics
• Utilizing advanced analytics and data visualization to develop a competitive advantage in a crowded market

Mike Spencer

Head of Real World Evidence, EMEA
Janssen

3:10 PM - 3:40 PM Networking Coffee Break

3:40 PM - 4:20 PM Harnessing Patient and Provider Information to Drive Improvement

Chris Day, Director of Engagement, Care Quality Commission
• Aligning around common goals - 5 key questions
• Ensure you measure what matters – where does the value lie?
• Provide audience driven insights through the effective utilisation of provider, public, and policy maker information
• Share and celebrate the industry potential of data driven change

Chris Day

Director of Engagement
Care Quality Commission
Round Tables:
• Explore strategies to tackle accessing and utilising Real World Data across different geo-markets
• Transform your market and payer approval – discuss the challenges of US developments in a European regulatory and ethical context
• Move towards Value Based Pricing – the importance of patient centricity in clinical treatments and follow-ups
• Discuss the role of data analytics and diagnostics as a means of deriving company strategy

Roman Affentranger

Head, Small Molecule Discovery Workflows, Research & Early Development
F. Hoffmann - La. Roche

Samantha Keyse

IT Director - Global RWE, PRA and Commercial Analytics
Eli Lilly